<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03126721</url>
  </required_header>
  <id_info>
    <org_study_id>B8271007</org_study_id>
    <secondary_id>2016-004238-50</secondary_id>
    <nct_id>NCT03126721</nct_id>
  </id_info>
  <brief_title>The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults</brief_title>
  <official_title>A Phase 1, Open-label, Fixed-sequence Design Study To Assess The Effect Of Multiple Dose Administration Of Pf-06751979 On The Single Dose Pharmacokinetics Of Oral Midazolam In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a drug interaction study to evaluate the PF-06751979 at steady state on the&#xD;
      pharmacokinetics of oral midazolam single doses in fixed sequences including single dose&#xD;
      midazolam alone in period 1 followed by multiple doses of 100 mg PF-06751979 once a day for&#xD;
      11 days with single dose midazolam co-administered on Day 10 in period 2&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Actual">July 11, 2017</completion_date>
  <primary_completion_date type="Actual">July 11, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>midazolam Area Under the Curve from time 0 to last quantifiable concentration (AUClast) in Period 1</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24 hrs post-dose</time_frame>
    <description>the plasma midazolam AUC from 0 to tlast (time of last quantifiable concentration) when a single oral midazolam dose given alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>midazolam Cmax on Day 1 in Period 1</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24 hrs post-dose</time_frame>
    <description>the midazolam Cmax when single oral midazolam dose given alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>midazolam Area Under the Curve from time 0 to infinite (AUCinf) in Period 1</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24 hrs post-dose</time_frame>
    <description>the plasma midazolam AUC from 0 to infinity when a single oral midazolam dose given alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>midazolam AUClast in Period 2</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 48 hrs post-dose</time_frame>
    <description>the plasma midazolam AUC from 0 to tlast (time of the last quantifiable concentration) when a single oral midazolam given in presence of steady state PF-06751979</description>
  </primary_outcome>
  <primary_outcome>
    <measure>midazolam Cmax in Period 2</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 48 hrs post-dose</time_frame>
    <description>the midazolam Cmax when a single oral midazolam given in presence of steady state PF-06751979</description>
  </primary_outcome>
  <primary_outcome>
    <measure>midazolam AUCinf in Period 2</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 48 hrs post-dose</time_frame>
    <description>the plasma midazolam AUC from 0 to infinity when a single oral midazolam given in presence of steady state PF-06751979</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>oral midazolam alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of oral midazolam administered alone in period 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral midazolam administered with multiple doses of PF-06751979</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of midazolam on day 10 with multiple doses of PF-06751979 once a day on Days 1-11 in period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>a single oral dose of 2 mg midazolam</description>
    <arm_group_label>oral midazolam administered with multiple doses of PF-06751979</arm_group_label>
    <arm_group_label>oral midazolam alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06751979</intervention_name>
    <description>multiple oral doses of PF-06751979 100 mg a day</description>
    <arm_group_label>oral midazolam administered with multiple doses of PF-06751979</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy female subjects of nonchildbearing potential and male subjects who, at the&#xD;
             time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is&#xD;
             defined as no clinically relevant abnormalities identified by a detailed medical&#xD;
             history, full physical examination, including blood pressure (BP) and pulse rate (PR)&#xD;
             measurement, 12-lead electrocardiogram (ECG), or clinical laboratory tests.&#xD;
&#xD;
          -  Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, (including alcoholic liver&#xD;
             disease, nonalcoholic steatohepatitis (NASH), autoimmune hepatitis, and hereditary&#xD;
             liver diseases), psychiatric, neurological, or allergic disease (including drug&#xD;
             allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of&#xD;
             dosing).&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (eg, gastrectomy).&#xD;
&#xD;
          -  Treatment with an investigational drug within 30 days (or as determined by the local&#xD;
             requirement) or 5 half-lives preceding the first dose of investigational product&#xD;
             (whichever is longer).&#xD;
&#xD;
          -  Subjects who have previously received PF-06751979.&#xD;
&#xD;
          -  Fertile male subjects who are unwilling or unable to use a highly effective method of&#xD;
             contraception as outlined in this protocol for the duration of the study and for at&#xD;
             least 28 days after the last dose of investigational product.&#xD;
&#xD;
          -  Use of prescription or nonprescription drugs and dietary supplements within 7 days or&#xD;
             5 half-lives (whichever is longer) prior to the first dose of investigational product.&#xD;
             As an exception, acetaminophen/paracetamol may be used at doses of &lt;=1 g/day. Limited&#xD;
             use of nonprescription medications that are not believed to affect subject safety or&#xD;
             the overall results of the study may be permitted on a case-by-case basis following&#xD;
             approval by the sponsor.&#xD;
&#xD;
          -  Herbal supplements and hormone replacement therapy must have been discontinued at&#xD;
             least 28 days prior to the first dose of investigational product.&#xD;
&#xD;
          -  Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more&#xD;
             within 60 days prior to dosing.&#xD;
&#xD;
          -  History of hypersensitivity to midazolam or any other benzodiazapine.&#xD;
&#xD;
          -  Other acute or chronic medical or psychiatric condition including recent (within the&#xD;
             past year) or active suicidal ideation or behavior or laboratory abnormality that may&#xD;
             increase the risk associated with study participation or investigational product&#xD;
             administration or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator, would make the subject inappropriate for entry into this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B8271007&amp;StudyName=A+Phase+1%2C+Open-label%2C+Fixed-sequence+Design+Study+To+Assess+The+Effect+Of+Multiple+Dose+Administration+Of+Pf-06751979+On+The+Single+Dose+Pharmacokinetics+Of+Oral+Midazolam+In+Healthy+Adult+Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>April 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug interaction</keyword>
  <keyword>PF-06751979</keyword>
  <keyword>oral midazolam</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

